BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210629
DTEND;VALUE=DATE:20210702
DTSTAMP:20260515T190245
CREATED:20210301T091950Z
LAST-MODIFIED:20210301T091950Z
UID:29192-1624924800-1625183999@www.pharmajournalist.com
SUMMARY:6th Microbiome Movement - Drug Development Summit
DESCRIPTION:Close the Clinical Gap\, Discover the Next Generation of Microbiome-based Therapeutics\, and Establish New Partnerships to Accelerate Your Research \nThe advancing scientific and clinical landscape mixed with the high-quality audience that we bring together has made this the must attend conference for those translating microbiome science into clinically successful therapeutics. \nThere is increased excitement around this years’ discussion; the community is now closer than ever to the first approved and commercially available microbiome-based therapeutic\, key functions are beginning to be understood and the number of clinical candidates are increasing. However\, there still remains an abundance of significant hurdles that must be overcome in order for continued success to be seen within the microbiome field. We are proud to bring together those at the forefront of tackling those challenges and is once again the centre of the 6th Microbiome Movement – Drug Development Summit. \n \nThe Microbiome Movement will provide the perfect opportunity for a collaborative approach between the biopharmaceutical and academic communities in order to pursue the causal role of the microbiome in disease and develop a new generation of microbiome-targeted therapeutics with predictable modes of action and consistent clinical outcomes. \nFrom understanding microbiome functionality\, leveraging lessons from clinical development and scaling manufacturing processes\, through to leveraging microbiome biomarkers for patient stratification and diagnostics\, our discussion will cover the latest scientific findings and industry updates from the end-to-end development of microbiome therapeutics. \nThere is still so much we can continue to do to make this complex science a clinical reality that improves the lives of patients\, and we hope that you can join this years’ discussion to help towards the development of effective treatments across a range of indications and push microbiome products closer to commercialization. \nTo know more about 6th Microbiome Movement – Drug Development Summit please click here.
URL:https://www.pharmajournalist.com/event/6th-microbiome-movement-drug-development-summit/
LOCATION:Virtual
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210629
DTEND;VALUE=DATE:20210702
DTSTAMP:20260515T190245
CREATED:20210309T092319Z
LAST-MODIFIED:20210309T092319Z
UID:29289-1624924800-1625183999@www.pharmajournalist.com
SUMMARY:Induced Proximity-Based Drug Discovery Summit
DESCRIPTION:Since the start of the 20th century\, there have been three major waves of innovation in drug discovery. We are now at the start of a fourth wave\, multispecific medicines\, that will pave the way for new treatments aimed at thousands of disease targets currently viewed as “undruggable”. By inducing proximity between two or more proteins\, multispecifics can harness the power of biology to go well beyond what conventional drugs can achieve. \n \nAs such\, the inaugural Induced Proximity-Based Drug Discovery Summit arrives as the dedicated scientific and networking forum for large pharma\, innovative biotech and research institutes to seize the endless potential of induced proximity- based drug discovery strategies to develop novel therapies for paradigm changing multispecific drugs of the future. \nJoin 100+ thought leaders of Chemically Biology\, Screening Biology and Molecular Biology from the likes of Amgen\, Ranok Therapeutics\, Proxygen and more at the Induced Proximity- Based Drug Discovery Summit to advance your knowledge\, differentiate your pipelines and be at the forefront of this new wave of innovation that will revolutionize drug discovery as currently known. \nTo know more about Induced Proximity-Based Drug Discovery Summit please click here.
URL:https://www.pharmajournalist.com/event/induced-proximity-based-drug-discovery-summit/
LOCATION:EST | Digital
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210629
DTEND;VALUE=DATE:20210702
DTSTAMP:20260515T190245
CREATED:20210312T075616Z
LAST-MODIFIED:20210312T080030Z
UID:29331-1624924800-1625183999@www.pharmajournalist.com
SUMMARY:JAK Inhibitors Drug Development Summit
DESCRIPTION:Returning to the digital stage this summer\, the 2nd JAK Inhibitors Drug Development Summit brings you the only dedicated JAK inhibitor conference that will allow you to utilize the knowledge of the greatest minds and thought leaders within the realms of the JAK pathway across dermatology\, rheumatology\, gastroenterology\, oncology and hematology. \nFocusing on optimized selectivity\, drug-drug interactions\, safety and efficacy challenges\, this summit will give you the insight to successfully translate and develop the next generation of superior JAK inhibitors. \nEnsure you attend this conference to learn\, to network and to strengthen your pipeline\, and implement the right clinical strategy.
URL:https://www.pharmajournalist.com/event/jak-inhibitors-drug-development-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210630
DTEND;VALUE=DATE:20210702
DTSTAMP:20260515T190245
CREATED:20210331T084111Z
LAST-MODIFIED:20210331T110431Z
UID:29602-1625011200-1625183999@www.pharmajournalist.com
SUMMARY:3rd Cell Engager Summit
DESCRIPTION:The 3rd Annual Cell Engager Summit is the only industry-led forum dedicated to developing multi-specific cell engaging therapies in liquid and solid tumor indications\, accelerating early discovery innovation into the clinic. \nThis forum comes at a critical point for the cell engager field as the success observed in the hematological field has not been obtained with solid tumors yet. Preclinical and early clinical data for cell engagers targeting solid tumors have been hugely promising. \nIf you are part of a research team that is looking to accelerate the approval of cell engager therapies\, then this conference has been curated with you in mind. \nBelow are a few highlights you won’t want to miss: \n\nDrive efficacy in solid tumors with solid tumor targets addressed by Roche\, Amgen\, Pfizer\, Merus\, andCompass Therapeutics\nModulate the immune system to drive efficacy via co-stimulatory targets in solid tumors with Xencor\, Harbour Biomed\, Crescendo Biologics\, Pieres\,and Aptevo\nHarness the power of the innate system for cell engagers and overcome the tumor microenvironment with Merck\, Lava Therapeutics\, Verseau Tx\, andoNKo-Innate\nImproving the therapeutic window of cell engagers – addressing toxicity\, half-life\, and CRS withAmunix\, Synaffix\, Revitope\, and TeneoBio\n\nTo know more about 3rd Cell Engager Summit please click here.
URL:https://www.pharmajournalist.com/event/3rd-cell-engager-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR